Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838858 | 0.74 | ALDH1A1 (0.47) | ALDH1A1DYRK1AHRH3HTTACP1 | |
| SCHEMBL840636 | 0.73 | ACP1 (0.39) | ALDH1A1HTTACP1 | |
| SCHEMBL839781 | 0.71 | ENPP2 (0.41) | ALDH1A1HRH3HTTACP1 | |
| SCHEMBL11304376 | 0.64 | LMNA (0.69) | SIGMAR1NPC1ALDH1A1KMT2A | |
| SCHEMBL1815400 | 0.62 | ALDH1A1 (0.58) | SIGMAR1NPC1ALDH1A1HTTKMT2A | |
| SCHEMBL4040184 | 0.62 | SIGMAR1 (0.74) | SIGMAR1L3MBTL1 | |
| SCHEMBL8023864 | 0.60 | SIGMAR1 (1.00) | SIGMAR1CCR3 | |
| Hydrochloric Acid SCHEMBL6370414 | 0.60 | SIGMAR1 (0.55) | SIGMAR1KMT2A | |
| SCHEMBL6328866 | 0.60 | SIGMAR1 (0.70) | SIGMAR1ALDH1A1CCR3 | |
| SCHEMBL24263805 | 0.59 | HDAC6 (0.51) | ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143246-B2 | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives | MSD OSS B.V. (NL) | 2012-03-27 | — | — | US | disclosed |
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | N.V.ORGANON | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144724-A1 | 1-(4-(PYRIDIN-2-YL)BENZYL)IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | OPRD1, CNR1, CNR2 | SIGMAR1 50/4885NPC1 4206/4885ACKR3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.